WASHINGTON, Nov. 8, 2024 /PRNewswire/ — At the NVIDIA AI Summit, Plato Systems presented its collaborative work with NVIDIA and shared its vision for the future of manufacturing, showcasing innovations in sensor fusion, AI agents, and digital twin technology, and highlighting how these advancements are set to revolutionize the industry.

Presenters:

Aria Pezeshk, Co-Founder & CTO, Plato SystemsAdam Scraba, Director of Product Marketing, NVIDIA Metropolis

To watch the full presentation visit: NVIDIA AI SUMMIT

Adam Scraba of NVIDIA quantified the massive challenge facing the manufacturing industry, “You can’t manage what you can’t measure.” Plato Systems has leveraged its Spatial Intelligence technology to deploy Vision Language Models (VLMs) that provide accurate self-service Vision Question Answering (VQA). This technology empowers various end users in factories to measure and manage different aspects of physical operations more effectively, driving significant improvements in efficiency and productivity. With these tools, factories can easily access, analyze, and aggregate data without needing in-house data specialists or going through expensive external solutions, delivering faster and more accurate insights for meaningful change.

Revolutionizing Physical Industries
Plato’s unique technology holds the potential to unlock the untapped value of digital transformation in physical industries, which are essential to 40% of global GDP (as highlighted by Samsara), by providing rapid feedback loops of operational insights that help boost operational efficiency and productivity in highly dynamic environments.

Advanced Spatial AI for Performance
Plato’s Spatial AI platform digitizes physical operations and organizes vast operational data streams, providing actionable insights through sophisticated spatio-temporal pattern recognition. The breakthrough VQA tools are built on NVIDIA Metropolis and NVIDIA AI Blueprints, and enable factories to harness the power of latest advances in AI to drive better performance.

Aria Pezeshk, Co-Founder & CTO of Plato Systems, emphasized:
“Our partnership with NVIDIA Metropolis has significantly accelerated our ability to adopt and deploy the latest advances in AI. The comprehensive tools and functionalities available within this ecosystem have streamlined our processes, allowing us to bring innovative solutions to our customers faster. As a result, our customers can leverage cutting-edge capabilities in LLMs and VLMs at scale and speed, transforming operations and enhancing their competitive edge.”

About Plato Systems

Founded in 2019 as a Stanford spin-off, Plato Systems leads the application of Spatial AI in manufacturing, digitizing and analyzing complex operator-machine interactions. Their operational digital twin platform identifies root causes of systemic issues at scale, transforming Kaizen and compliance tracking. Major manufacturers across the U.S., Japan, and Mexico are using Plato’s platform to boost capacity and productivity without increasing capital expenditures or labor costs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/plato-systems-showcases-ai-powered-factory-of-the-future-at-the-nvidia-ai-summit-302300177.html

SOURCE Plato Systems

SINGAPORE, Nov. 9, 2024 /PRNewswire/ — HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present its latest research findings and advancements in AI-based analysis at the 75th The Liver Meeting® (TLM) 2024, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which brings together leading scientists, clinicians, and industry experts in hepatology, will be held from November 15th to 19th, in San Diego, California.

HistoIndex’s team, including the KOLs involved in the studies, will be sharing insights into the company’s innovative approach to assess regression and progression of liver fibrosis, including groundbreaking AI-enabled methodology that enhance the detection, quantification, and assessment of various liver conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and fibrosis. With the incidence of liver diseases rising globally, these presentations are timely in showcasing how HistoIndex’s stain-free digital pathology solutions and AI technology address current challenges by providing highly accurate, reproducible, and interpretable data from liver biopsies.

As a leader in AI-based analysis using stain-free digital pathology, we are honored to have extensive representation at TLM 2024, showcasing twelve abstracts from phase 2b and phase 3 clinical trials that span four distinct mechanisms of action (MOA) in MASH. Commenting on the significance of the accepted abstracts, Dr. Dean Tai, Chief Scientific Officer at HistoIndex stated, “These findings from the four distinct MOA phase 2b/3 MASH trials, along with diverse studies highlighting the utility of our technology in cirrhotic MASH, differentiating pediatric and adult MASH, predicting clinical outcomes, and understanding hepatocellular carcinoma recurrence in chronic hepatitis B patients, underscore the transformative role of AI in advancing liver disease diagnosis, prognosis and personalized treatment. We are excited to share these advancements and their impact on clinical trials leading to routine clinical care.”

Key Highlights from HistoIndex at TLM 2024

The HistoIndex team will be involved in multiple oral and poster sessions, highlighting its commitment to advancing liver research and supporting the global hepatology community:

Oral Presentation | Sunday, November 17th, 2.45pm – 3pm
Title: AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 study
Presenter: Dr. Mary Rinella
Publication Number: 170

Poster Presentations

Poster Session I | Friday, November 15th, 1:00 PM – 2:00 PM

Title: Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease
Presenter: Dr Zhengxin Li
Publication Number: 1561

Title: The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients
Presenter: Dr Ke Yin
Publication Number: 1275

Poster Session II | Saturday, November 16th, 1:00 PM – 2:00 PM

Title: Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis.
Presenter: Dr Naim Alkhouri
Publication Number: TBC

Title: Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation
Presenter: Dr Kutbuddin Akbary
Publication Number: 2114

Title: Evaluation of the consistency and heterogeneity of adjacent sections in fibrosis assessment using AI-based qFibrosis in virtual liver needle biopsies
Presenter: Dr Yayun Ren
Publication Number: 2047

Title: Independent validation of second harmonic generation/two photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment
Presenter: Dr Kutbuddin Akbary
Publication Number: 2065

Title: Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease
Presenter: Dr Jonathan Fallowfield
Publication Number: 2080

Poster Session III | Sunday, November 17th, 1:00 PM – 2:00 PM

Title: Fibrosis regression after Tirzepatide treatment of non-cirrhotic MASH for 52 weeks occurs in a zone-dependent manner
Presenter: Dr Arun Sanyal
Publication Number: 3202

Title: Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH
Presenter: Dr Jörn Schattenberg
Publication Number: 3184

Poster Session: Late Breaking Posters | Monday, November 18th: 8:00 AM – 5:00 PM

Title: AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with Efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study
Presenter: Dr Mazen Noureddin
Publication Number: 5047

Title: Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
Presenter: Dr Mazen Noureddin
Publication Number: 5021

Breakfast Meeting: Bridging Clinical Research and Clinical Care

In addition to the scientific sessions, HistoIndex will be hosting a breakfast meeting on November 15th, offering a unique opportunity for clinicians, researchers, and industry partners to interact with the HistoIndex team and KOLs on the transformative potential of AI-based analysis using stain-free digital pathology in current MASH clinical trials and its role in the routine clinical care of MASH patients post drug approvals. If you are keen, please register here today at https://forms.gle/2gBJ6mvSeadHHBNi6.

Visit HistoIndex at Booth #1225

All attendees of TLM 2024 are invited to visit the HistoIndex exhibition booth #1225 and experience the company’s Second Harmonic Generation (SHG) technology and AI-enabled analytics with hands-on interactive demonstrations. The exhibition booth will be staffed by knowledgeable company representatives eager to engage with attendees and discuss potential partnerships.

For more information about HistoIndex’s participation in TLM 2024, please visit www.histoindex.com.

About HistoIndex

Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining cutting-edge biophotonic technology with AI-based analysis, HistoIndex provides innovative tools to improve the assessment of fibrosis changes and drug efficacy. The Company’s breakthrough digital pathology solutions are accelerating research, expediting pharmaceutical drug development, and transforming medical standards.

View original content:https://www.prnewswire.com/apac/news-releases/histoindex-to-present-latest-findings-on-ai-based-analysis-using-stain-free-digital-pathology-with-12-accepted-abstracts-at-aasld-the-liver-meeting-2024-302298451.html

SOURCE HistoIndex

SUWON, South Korea, Nov. 8, 2024 /PRNewswire/ — Park Systems (CEO Dr. Sang-il Park), a leading provider of nanometrology solutions with Atomic Force Microscopy (AFM) and Imaging Spectroscopic Ellipsometry (ISE), is proud to announce a new partnership with Labindia Instruments Pvt. Ltd. for business expansion in India.

Park Systems started its business in India in 2008 and has been recognized to be a major player in nanoscience metrology, installing 100+ AFM and ISE systems in science and technology institutes in India. This partnership unites Labindia’s expertise in scientific instrument distribution with Park Systems’ innovative AFM to expand its reach both in India’s science research area and India’s rapidly growing semiconductor sector.

India has recently embarked on a major semiconductor manufacturing initiative, India Semiconductor Mission (ISM), driven by the Prime Minister Narendra Modi and the government. India Semiconductor Mission (ISM) aims to be a new global hub for semiconductor and display industry. As industry moves forward, AFMs are becoming a critical technology for semiconductor and display sample analysis. This partnership comes at an ideal time, with rising interest from professors, engineers, and students in advanced semiconductor technologies.

“With the rapid advancement of India’s semiconductor industry, the need for precise metrology instruments has never been greater,” said Dr. Sang-Joon Cho, Executive Vice President at Park Systems. “Labindia’s proven track record and extensive network make them an ideal partner for us as we strengthen our presence in the Indian market.”

Labindia brings decades of experience and significant manpower, making them a well-established player in India’s scientific community. As one of the most influential distributors in the region, their expertise in sales, customer service and technical support across India’s metrology sector will help Park Systems meet the growing demand for high-performance AFM and related technologies.

Park Systems is poised to solidify its reputation and influence within India’s burgeoning semiconductor industry, which is expected to become one of the world’s largest in the coming years. The company’s participation in SEMICON India and AsiaNano2024 and its ongoing engagement with India’s top researchers and engineers further position it as a leader in nanoscale analysis technologies.

About Park Systems Corp. (KOSDAQ: 140860)
Park Systems is a leading manufacturer of atomic force microscopy (AFM) and nano metrology systems, catering to researchers and engineers in diverse fields such as materials science, physics, chemistry, life sciences, semiconductors, and data storage. The company’s mission is to drive nanoscale innovations that address global challenges and advance scientific discoveries. Park Systems’ clients include top semiconductor companies and research universities worldwide. With headquarters in Suwon, Korea, and regional offices across the Americas, Europe, and Asia, Park Systems is publicly traded on the Korea Stock Exchange. Learn more at http://www.parksystems.com

About Labindia
Labindia Instruments Pvt. Ltd., founded in 1982 is a premier distributor of scientific and analytical instruments in India, providing solutions across metrology, life sciences, petroleum, and material science sectors. With a broad network and extensive technical expertise, Labindia has established itself as a trusted partner for global companies entering the Indian market. Learn more at www.labindiainstruments.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/park-systems-india-announces-new-strategic-partnership-with-labindia-instruments-302299924.html

SOURCE Park Systems Corp.